SEARCH:   Advanced

Blood, 1 March 2004, Vol. 103, No. 5, pp. 1862-1868. Prepublished online as a Blood First Edition Paper on November 13, 2003; DOI 10.1182/blood-2003-04-1359. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-04-1359v1 103/5/1862    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Houldsworth, J. Articles by Chaganti, R. S. K. Search for Related Content PubMed PubMed Citation Articles by Houldsworth, J. Articles by Chaganti, R. S. K. Related Collections Neoplasia Oncogenes and Tumor Suppressors Gene Expression Genomics Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas Jane Houldsworth, Adam B. Olshen, Giorgio Cattoretti, Gerard B. Donnelly, Julie Teruya-Feldstein, Jing Qin, Nallasivam Palanisamy, Yingjing Shen, Katerina Dyomina, Marina Petlakh, Qiulu Pan, Andrew D. Zelenetz, Riccardo Dalla-Favera, and R. S. K. Chaganti From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA. Although it has been suggested that REL is the critical target gene of 2p12-16 amplification in diffuse large B-cell lymphoma (DLBCL), little experimental evidence supports this notion. In the present study, we sought to evaluate the relationship between REL amplification and REL function in a panel of 46 newly diagnosed DLBCLs and to correlate with DLBCL subgroups as identified by gene expression profiles and clinical features. The results indicate that amplification of the REL locus is not associated with accumulation of the active form of REL, as evaluated by immunofluorescence analysis. Upon subgrouping of the DLBCL cases based on gene expression signatures, REL amplification was detected in all subgroups, while high levels of nuclear-located REL were more frequently detected in activated B-cell–like DLBCL. Correlative analyses of REL copy number and REL nuclear accumulation with clinical parameters did not reveal any significant associations. Together these results indicate that 2p12-16 amplification does not lead to abnormal REL activation, suggesting that REL may not be the functional target of the amplification event. Nonetheless, these data indicate that DLBCLs are heterogeneous with respect to REL and thus nuclear factor–B (NF-B) activity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: RELevant gene amplification in B-cell lymphomas? Thomas D. Gilmore, Daniel T. Starczynowski, Demetrios Kalaitzidis, R. S. K. Chaganti, and Jane Houldsworth Blood 2004 103: 3243-3245. [Full Text] [PDF] This article has been cited by other articles: F. Jardin, P. Ruminy, J.-P. Kerckaert, F. Parmentier, J.-M. Picquenot, S. Quief, C. Villenet, G. Buchonnet, M. Tosi, T. Frebourg, et al. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas Haematologica, April 1, 2008; 93(4): 543 - 550. [Abstract] [Full Text] [PDF] D. Rossi and G. Gaidano CD40 promotes lymphoma from nuclear hideaway Blood, September 15, 2007; 110(6): 1710 - 1711. [Full Text] [PDF] S. Parekh, J. M. Polo, R. Shaknovich, P. Juszczynski, P. Lev, S. M. Ranuncolo, Y. Yin, U. Klein, G. Cattoretti, R. D. Favera, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms Blood, September 15, 2007; 110(6): 2067 - 2074. [Abstract] [Full Text] [PDF] C. Andreadis, P. A. Gimotty, P. Wahl, R. Hammond, J. Houldsworth, S. J. Schuster, and T. R. Rebbeck Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma Blood, April 15, 2007; 109(8): 3409 - 3416. [Abstract] [Full Text] [PDF] S. Uddin, A. R. Hussain, A. K. Siraj, P. S. Manogaran, N. A. Al-Jomah, A. Moorji, V. Atizado, F. Al-Dayel, A. Belgaumi, H. El-Solh, et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood, December 15, 2006; 108(13): 4178 - 4186. [Abstract] [Full Text] [PDF] C. Andreadis, P. Gimotty, R. Hammond, P. Wahl, J. Houldsworth, S. Schuster, and T. Rebbeck Expression Levels of Glutathione Peroxidase 1 (GPx1) and Multi-Drug Resistance 1 (MDR1; ABCB1) Identify Patients with Diffuse Large B-Cell Lymphoma (DLBCL) That Have Superior Clinical Outcomes. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 839 - 839. [Abstract] [PDF] L. Bernal-Mizrachi, C. M. Lovly, and L. Ratner The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas PNAS, June 13, 2006; 103(24): 9220 - 9225. [Abstract] [Full Text] [PDF] W. Chen, J. Houldsworth, A. B. Olshen, G. Nanjangud, S. Chaganti, E. S. Venkatraman, J. Halaas, J. Teruya-Feldstein, A. D. Zelenetz, and R. S. K. Chaganti Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas Blood, March 15, 2006; 107(6): 2477 - 2485. [Abstract] [Full Text] [PDF] C. H. Moskowitz, A. D. Zelenetz, T. Kewalramani, P. Hamlin, S. Lessac-Chenen, J. Houldsworth, A. Olshen, R. Chaganti, S. Nimer, and J. Teruya-Feldstein Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL Blood, November 15, 2005; 106(10): 3383 - 3385. [Abstract] [Full Text] [PDF] A. Hachem and R. B. Gartenhaus Oncogenes as molecular targets in lymphoma Blood, September 15, 2005; 106(6): 1911 - 1923. [Full Text] [PDF] J. S. Abramson and M. A. Shipp Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood, August 15, 2005; 106(4): 1164 - 1174. [Abstract] [Full Text] [PDF] F. Feuerhake, J. L. Kutok, S. Monti, W. Chen, A. S. LaCasce, G. Cattoretti, P. Kurtin, G. S. Pinkus, L. de Leval, N. L. Harris, et al. NF{kappa}B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes Blood, August 15, 2005; 106(4): 1392 - 1399. [Abstract] [Full Text] [PDF] A. Lopez-Guillermo, L. Colomo, M. Jimenez, F. Bosch, N. Villamor, L. Arenillas, A. Muntanola, S. Montoto, E. Gine, D. Colomer, et al. Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin J. Clin. Oncol., April 20, 2005; 23(12): 2797 - 2804. [Abstract] [Full Text] [PDF] L. Pasqualucci, R. Guglielmino, J. Houldsworth, J. Mohr, S. Aoufouchi, R. Polakiewicz, R. S. K. Chaganti, and R. Dalla-Favera Expression of the AID protein in normal and neoplastic B cells Blood, November 15, 2004; 104(10): 3318 - 3325. [Abstract] [Full Text] [PDF] T. D. Gilmore, D. T. Starczynowski, D. Kalaitzidis, R. S. K. Chaganti, and J. Houldsworth RELevant gene amplification in B-cell lymphomas? Blood, April 15, 2004; 103(8): 3243 - 3245. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020